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Abstract  29 
Therapy of autoimmune diseases in dogs and people currently relies on use of broad-spectrum 30 
immunosuppressive drugs, which are associated with unacceptable adverse effects in some patients. 31 
Detractions of broad-spectrum immunosuppressive drugs are particularly apparent in people and 32 
animals with autoimmune haemolytic anaemia (AIHA), in whom such therapy is often required at 33 
high doses and for prolonged periods.   Greater understanding of the immune aberrations that occur in 34 
patients with AIHA has permitted development of several forms of novel immunotherapy, which are 35 
intended to re-establish tolerance of self-antigens rather than suppress all parts of the immune system.  36 
Such therapies should be efficacious while still permitting normal responses to pathogens and 37 
inoculation.  Immunotherapies of particular interest include monoclonal antibodies that produce 38 
selective depletion of the B cell compartment to decrease autoantibody production, administration of 39 
peptide antigens by subcutaneous or sublingual routes to establish tolerance, adoptive transfer of 40 
regulatory T cells (Tregs), and administration of low dose recombinant interleukin 2 to encourage 41 
proliferation and activation of Tregs.  These therapies are in variable stages of development, with 42 
some being trialled in people and client-owned dogs, and others undergoing validation in 43 
experimental murine models.  Continued development of these immunotherapies is likely to lead to 44 
the introduction of several novel products for the management of autoimmune disease in veterinary 45 
practice in the future. 46 
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Introduction 56 
 57 
Autoimmune diseases are caused by the development of inappropriate immune responses directed 58 
against host antigens.  Ordinarily, the immune system remains tolerant of self-antigens through a 59 
number of mechanisms, beginning with deletion of autoreactive T cells in the thymus and B cells in 60 
bone marrow (Mouchess and Anderson, 2014).  This process is insufficient to maintain immune 61 
tolerance because not all autoreactive cells are deleted and because mature lymphocytes may be 62 
exposed to cryptic antigens, such as after entry into the eye, brain, testis or other immunologically 63 
privileged sites (Forrester et al., 2008).  The activity of mature T cells emigrating from the thymus is 64 
therefore regulated to limit development of responses to self-antigens, while permitting differentiation 65 
of effector cells capable of responding to exogenous insults.  This regulation, synonymous with 66 
maintenance of peripheral tolerance, is manifest in the complex interaction of physical barriers, 67 
soluble signalling molecules and synapses between cells of the innate and adaptive immune systems, 68 
of which one important participant is the regulatory T cell (Treg) (Sakaguchi et al., 2009).   69 
 70 
Regulatory T cells:  The term Treg is now generally applied to a group of CD4+ T cells recognised in 71 
mice and people by their surface expression of the interleukin (IL)-2 receptor alpha chain, CD25, and 72 
by expression of the transcription factor Forkhead box Protein 3 (FoxP3), which is required for their 73 
differentiation and function (Brunkow et al., 2001; Hori et al., 2003).  The presence of a functional 74 
thymus is required for development of these thymic Tregs (Kojima and Prehn, 1981), though similar 75 
cells can differentiate in the periphery (Yadav et al., 2013). As in other species, a group of CD4+ T 76 
cells that expresses FoxP3 and displays CD25 has been described in dogs (Garden et al., 2011; 77 
Knueppel et al., 2011; Pinheiro et al., 2011), in which they were also capable of suppressing non-78 
specific proliferation of T cells in vitro.  A more recent study of the markers expressed by human 79 
CD4+CD25+FOXP3+ T cells suggests that many different subdivisions of this group will be 80 
recognised in future using emerging methodologies such as flow spectrometry, though the functional 81 
characteristics of these sub-groups have yet to be investigated (Mason et al., 2015).   82 
Regulatory T cells are able to suppress the activation and proliferation of effector T cells (CD4+ cells 83 
with Th1, Th2, Th9, Th17 and other phenotypes) and cytotoxic T cells in vitro when the latter cells 84 
are activated by either polyclonal or specific antigenic stimuli (Thornton et al., 1998; Dieckmann et 85 
al., 2001; Wing et al., 2003).  Corresponding effects are observed in vivo, with suppression of 86 
transplant rejection and cessation of deleterious autoimmune responses observed after adoptive 87 
transfer of Tregs into experimental animals (Graca et al., 2002; Hoffmann et al., 2002; Buckner, 88 
2010).  The importance of Tregs is also demonstrated by mice that have undergone thymectomy 89 
(Kojima and Prehn, 1981; Sakaguchi et al., 1985), adult mice in which Tregs have been depleted 90 
pharmacologically (Ellis et al., 2013; Kim et al., 2007) and people and mice that are unable to express 91 
FOXP3/foxp3 in Tregs (Bennett et al., 2001; Brunkow et al., 2001; Wildin et al., 2001), all of which 92 
develop multisystemic autoimmune diseases.   93 
 94 
Investigations of Tregs in people with spontaneous autoimmune diseases have yielded results that are 95 
more equivocal, possibly because findings may depend on the types of samples collected and the 96 
gating strategies used to define Tregs using flow cytometry.  For example, in people with rheumatoid 97 
arthritis, the frequency of Tregs in blood has been reported to be normal (Aerts et al., 2008), increased 98 
(Han et al., 2008) or decreased (Cao et al., 2004) in different studies, whereas Tregs are consistently 99 
increased in synovial fluid of inflamed joints (Miyara et al., 2011).  Changes in peripheral blood 100 
Tregs in various human autoimmune diseases have been summarised elsewhere (Miyara et al., 2011; 101 
Grant et al., 2015). 102 
 103 
Preliminary investigations of Tregs in canine immune-mediated diseases have yielded similarly mixed 104 
results.  Decreased frequencies of Tregs were described in the blood of dogs with primary immune-105 
mediated thrombocytopaenia and chronic enteropathies compared to healthy control dogs in a small 106 
pilot study (Volkmann et al., 2014), but frequencies were not different from healthy dogs after the 107 
clinical signs of both diseases were controlled.  In a separate study, the proportion of T cells that 108 
expressed both CD4 and FoxP3 did not differ between healthy dogs and dogs with primary 109 
hypothyroidism (Miller et al., 2015). 110 
 111 
Immune-mediated haemolytic anaemia in people and dogs:  One autoimmune disease in which the 112 
role of Tregs is not fully defined is autoimmune haemolytic anaemia (AIHA), which was first 113 
described in a human patient by Vanlair and Masius in 1871 (Packman, 2001).  The disease is 114 
characterised by production of antibodies directed against normal glycoprotein antigens on the surface 115 
of erythrocytes.  Anti-erythrocyte antibodies are produced normally to assist in clearance of senescent 116 
cells (Lutz and Wipf, 1982); in people with AIHA, the antibodies facilitate complement-mediated 117 
intravascular haemolysis or phagocytosis of opsonised erythrocytes in the liver and spleen (Berentsen 118 
and Tundic, 2015), resulting in anaemia that is often severe.  Autoimmune haemolytic anaemia is 119 
classified according to the activity of autoantibodies at different temperatures: the most common form 120 
is ‘warm’ AIHA, in which antibodies are capable of causing haemolysis at 37oC, which differentiates 121 
the disease from several forms of cold agglutinating disease (CAD), in which antibodies are most 122 
active at 3-4oC (Berentsen and Tundic, 2015).  Warm AIHA bears strong resemblance to canine 123 
primary immune-mediated haemolytic anaemia (IMHA), which is considered to be the most common 124 
autoimmune disease of dogs (McCullough, 2003).  Both diseases cause severe anaemia that typically 125 
develops acutely and may be accompanied by pre-hepatic icterus (Swann and Skelly, 2011; Berentsen 126 
and Tundic, 2015).   127 
 128 
Studies of people with warm AIHA indicate that the aberrant autoimmune response may have a Th17 129 
phenotype; the frequency of Th17 cells in peripheral blood was increased in people with AIHA 130 
compared to healthy controls and these and the serum concentration of IL-17 were correlated with the 131 
severity of clinical disease (Hall et al., 2012; Xu et al., 2012).  A further study indicated that the 132 
frequency of Tregs was decreased in people with warm AIHA compared to healthy volunteers, and 133 
this also correlated with some markers of disease severity (Ahmad et al., 2011).  There are no 134 
published studies describing numbers or suppressive function of Tregs in dogs with primary IMHA, 135 
but this is an area of active investigation in our own laboratory.  A single abstract described an 136 
unusually high average frequency of Tregs as a proportion of total lymphocytes (24.84%) in seven 137 
affected dogs (Baek et al., 2013). 138 
 139 
Therapy of autoimmune diseases:  In clinical practice today, autoimmune diseases are treated with 140 
immunosuppressive agents that frequently have an effect on many parts of the immune system 141 
simultaneously.  While often effective, these drugs may be associated with adverse effects because 142 
they suppress immune responses directed at all antigens, including exogenous pathogens.  Also, 143 
because these drugs do not induce tolerance of self-antigens, there is a continued risk of relapse 144 
during and after treatment, such that a very long or indefinite course of treatment is often required.  145 
Owing to the detractions inherent in immunosuppressive treatment, much current research is directed 146 
at generation of immunomodulatory therapies that induce or re-instate peripheral tolerance of self-147 
antigens, either by altering responses of effector T cells or by increasing numbers or activity of Tregs 148 
(Figure 1). 149 
 150 
Rationale for and implications of immunosuppressive treatment:  There has been a pleasing and 151 
saleable symmetry about the use of immunosuppressive drugs for the treatment of autoimmune 152 
diseases in people and animals since the discovery and widespread production of the synthetic 153 
corticosteroids in the 1950s (Herzog and Oliveto, 1992).  Indeed, glucocorticoids remain the only 154 
group of drugs licensed for the treatment of autoimmune diseases in dogs and cats in the UK1 and, in 155 
a recent systematic review of evidence relating to the treatment of IMHA in dogs, we found that 156 
glucocorticoids had been administered to all of the 843 dogs from which data were derived (Swann 157 
and Skelly, 2013).  Use of prednisolone (or prednisone) alone seems to result in survival rates of up to 158 
65% at six months after diagnosis (Swann and Skelly, 2013), with similar response rates reported in 159 
people (Zanella and Barcellini, 2014).  There are concerns that long-term administration of these 160 
drugs may result in unacceptable adverse effects, largely due to iatrogenic recapitulation of Cushing’s 161 
syndrome and increased risk of thromboembolic disease (Rose et al., 2011). 162 
 163 
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In order to facilitate a polypharmaceutical approach to the management of autoimmune disease, 164 
several other immunosuppressive drugs have been used in medical and veterinary practice, as has 165 
been reviewed elsewhere (Whitley and Day, 2011; Zanella and Barcellini, 2014).  Adoption of 166 
combination therapies for treatment of dogs with IMHA is conceptually attractive but is not proven to 167 
result in improved survival or decreased prevalence of glucocorticoid-associated adverse effects 168 
(Swann and Skelly, 2013).  Indeed, concurrent use of immunosuppressive drugs that act on different 169 
components of the immune response may produce additional risks, such as development of cutaneous 170 
fungal infections in dogs receiving ciclosporin and glucocorticoids (Dowling et al., 2015). 171 
 172 
Greater understanding of the immunological changes that occur in people and animals with 173 
autoimmune diseases has also informed the use of some immunosuppressive drugs.  Epidemiological 174 
studies revealed that the alkylating agent cyclophosphamide had a paradoxical effect, causing immune 175 
stimulation at low doses and immunosuppression at high doses, as reviewed elsewhere (Heylmann et 176 
al., 2013).  Investigations in people and mice have shown that Tregs are particularly sensitive to the 177 
lymphotoxic effects of cyclophosphamide at low doses, favouring increased activity of effector 178 
components of the immune system (Brode and Cooke, 2008).  While this effect is beneficial to 179 
prevent immune evasion of neoplastic cells in patients receiving metronomic chemotherapy 180 
(Schabowsky et al., 2007), it is interesting to note that administration of cyclophosphamide was 181 
associated with a poorer outcome in dogs with IMHA in two small epidemiological studies (Reimer et 182 
al., 1999; Grundy and Barton, 2001), possibly related to its effects on Tregs.  In contrast, the same 183 
drug has been used at high doses in people to achieve control of AIHA that has not responded to 184 
glucocorticoids or other forms of conventional treatment, resulting in clinical remission in five of 185 
eight patients in one study (Moyo et al., 2002). 186 
 187 
Monoclonal antibody therapy:  People with AIHA who have failed treatment with glucocorticoids 188 
are frequently treated with rituximab, a human/murine chimeric monoclonal antibody specific for the 189 
human CD20 molecule.  Exclusive expression on the surface of B cells makes this molecule an 190 
attractive target in diseases characterised by autoantibody production; binding of rituximab facilitates 191 
complement-mediated destruction and antibody-mediated cell cytotoxicity, resulting in rapid 192 
depletion of the B cell compartment in blood, lymphoid tissue and bone marrow (Reff et al., 1994).  193 
Since the first report of its use in people with warm AIHA in 2002 (Zaja et al., 2002), more than 20 194 
studies have evaluated its effects.  A recent meta-analysis of data from 409 people concluded that the 195 
overall response rate was 79% (95% confidence interval [CI] 60-90%) in people with warm AIHA, 196 
and that the rate of overall and complete response was higher in this group of patients compared to 197 
those with other forms of AIHA in univariable meta-regression analysis (Reynaud et al., 2015).  In 198 
one study, the majority of patients making a complete response remained in remission for at least six 199 
months, with responses more likely in younger patients and those with a shorter duration of disease 200 
prior to receiving rituximab (Penalver et al, 2010; Barcellini et al, 2013; Reynaud et al, 2015).  201 
 202 
Monoclonal antibodies have a more restricted immunosuppressive effect than glucocorticoids and 203 
other broad-spectrum immunosuppressive drugs, but they still increase the risk of opportunistic 204 
infections.   Adverse effects were observed in approximately 14% (95% CI 9-21) of people treated 205 
with rituximab in the meta-analysis described in the preceding paragraph (Reynaud et al., 2015), with 206 
severe infections, neutropaenia and Pneumocystis jirovecii pneumonia representing the most inimical.  207 
Monoclonal antibodies, though usually humanised or composed of chimeric murine and human 208 
elements, may still be recognised as foreign antigens by the immune system, resulting in development 209 
of responses that neutralise their effects (Keiserman et al., 2014).  Finally, depletion of the B cell 210 
compartment may also create niches in the spleen that are conducive to survival of long-lived 211 
autoreactive plasma cells, which would not otherwise persist in the face of conventional 212 
immunosuppressive treatment.  This phenomenon has been demonstrated in studies of people with 213 
warm AIHA and immune-mediated thrombocytopaenia that received rituximab before undergoing 214 
splenectomy owing to failure to control their clinical signs (Mahevas et al., 2013; 2015), though this 215 
has not been associated with increased risk of relapse.     216 
 217 
Rituximab was manufactured for specificity to epitopes on the extracellular domain of human CD20.  218 
The structure of this domain varies among mammalian species (Polyak and Deans, 2002), but the 219 
functional importance of this diversity is unknown because the physiological ligand for CD20 has yet 220 
to be identified.  Consequent to these differences in structure, rituximab does not cross react with the 221 
extracellular domain of canine molecules (Jubala et al., 2005) and has no apparent therapeutic 222 
potential in this species, as demonstrated by failure to deplete B cells in an ex vivo model of B cell 223 
lymphoma (Impellizeri et al., 2006).  Nevertheless, established methodologies have been applied to 224 
develop monoclonal ‘caninised’ antibodies that bind CD20 and deplete B cells in dogs (Ito et al., 225 
2015; Rue et al., 2015).  One such product has been licensed in the United States, and clinical trials 226 
are currently ongoing to evaluate its efficacy in the management of canine lymphoma2 (Rodriguez et 227 
al., 2015).       228 
 229 
Autoantigen-specific immunotherapy:  Production of antibodies with high affinity for antigen does 230 
not occur without provision of stimulatory signals from T helper cells, which premise has led to 231 
renewed interest in the role of these cells in autoimmune diseases.  Naïve T cells become activated 232 
when they recognise their cognate antigens presented in the context of major histocompatibility 233 
(MHC) molecules, but mounting evidence suggests that the concentration, preparation and route of 234 
entry of the antigen into the body can have a major impact on the nature of the immune response that 235 
develops (Verhagen et al., 2015).  For example, experiments in the early twentieth Century showed 236 
that administration of pollen extracts to patients with pollen hypersensitivity (hay fever) by 237 
subcutaneous injection could alleviate or completely resolve their clinical signs, whereas the same 238 
allergens would be detrimental if encountered naturally (Ring and Gutermuth, 2011).  These 239 
observations led to the development of allergen-specific immunotherapy protocols for use in this and 240 
other hypersensitivity diseases (Jutel et al., 2015), and delivery of allergens by subcutaneous or 241 
sublingual routes is also widely practiced in veterinary medicine for management of canine atopic 242 
dermatitis (Olivry et al., 2015; Mueller et al., 2015).  243 
 244 
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Several experimental models suggest that the same process could be applied to control established 245 
autoimmune responses (Sabatos-Peyton et al., 2010).  This autoantigen-specific immunotherapy is 246 
based primarily on the ability to induce Th1, Th2 and Th17 cells to adopt a regulatory phenotype 247 
characterised by production of IL-10 (Meiler et al., 2008) and possibly by display of the surface 248 
markers CD49b and LAG-3 (Gagliani et al., 2013) in response to their cognate antigens.  Effector T 249 
cells are more likely to differentiate into these so-called Tr1 cells (also described as IL-10Tregs cells) 250 
when exposed to repeated, high doses of their cognate antigens delivered by subcutaneous injection, 251 
though, in patients with clinically active diseases, there are concerns that such dosing schedules could 252 
exacerbate of the autoimmune response.   253 
 254 
The latter phenomenon was observed in three patients with multiple sclerosis who received 255 
subcutaneous injections of a peptide derived from the immunodominant myelin basic protein.  These 256 
patients suffered more severe neurological abnormalities and brain inflammation (as indicated by 257 
magnetic resonance imaging) but were subsequently rescued by administration of glucocorticoids 258 
(Bielekova et al., 2000).  Elucidation of immunological changes revealed that administration of the 259 
autoantigen was associated with increased numbers of Th1 effector cells in the cerebrospinal fluid of 260 
some patients, rather than induction of anergy or differentiation of Tr1 cells.  While notably this study 261 
used an altered peptide antigen, in which some amino acids had been artificially substituted to modify 262 
the interaction at the synapse between T cell and MHC-peptide complex, this study demonstrates the 263 
risks inherent in autoantigen-specific immunotherapy and the need for a dosing schedule that 264 
minimises them.    265 
 266 
Autoantigen-specific immunotherapy has not been attempted in people with AIHA or dogs with 267 
IMHA, but this form of treatment could be feasible in both species because previous studies have 268 
identified several of the immunodominant self-antigens targeted by autoimmune responses.  In 269 
people, autoantibodies are most commonly specific for epitopes on the Rhesus polypeptides (Barker 270 
et al., 1992), and T cells from patients with AIHA showed a proliferative response in vitro to peptides 271 
derived from the Rhesus D molecule (Barker et al., 1997).  In dogs with IMHA, autoreactive T and B 272 
cells are more likely to be specific for glycophorin molecules, though patterns of reactivity to 273 
erythrocyte antigens do not appear to be as consistent between individuals as in people (Barker et al., 274 
1991; Corato et al., 1997). 275 
 276 
In people with warm AIHA, T cells that produce IL-10 in response to Rhesus D molecules have also 277 
been identified in the spleen and peripheral blood.   These cells were able to suppress production of 278 
the Th1-associated cytokine interferon gamma (IFNγ) in peripheral blood mononuclear cell cultures 279 
in vitro, contingent on their expression of CTLA-4 (Hall et al., 2002; Ward et al., 2008).  These 280 
studies suggest that Tr1 cells are present in the blood of people with AIHA, where they could be 281 
activated or induced by administration of autoantigen in an appropriate form. 282 
 283 
Cell-based therapy:  Whether or not defects in Treg frequency or function contribute to development 284 
of autoimmune diseases, there is growing evidence to suggest that they could be used as a therapeutic 285 
agent to re-establish tolerance of self-antigens.  In support of this notion, adoptive transfer of splenic 286 
CD4+CD25+ Tregs prevented production of anti-erythrocyte antibodies in mice that were 287 
subsequently injected repeatedly with rat erythrocytes to generate an autoimmune response (in the 288 
Playfair Marshall-Clarke model of AIHA)(Mqadmi et al., 2005).  Studies in other murine models of 289 
autoimmune disease have shown that similar adoptive transfers can ameliorate established 290 
autoimmune diseases and delay or prevent rejection of transplanted organs, as reviewed elsewhere 291 
(Singer et al., 2014).   292 
 293 
There have been numerous obstacles in the path to use Tregs as therapy for people with autoimmune 294 
diseases, including the need to isolate Tregs from peripheral blood using reliable phenotypic markers, 295 
expand the number of Tregs in ex vivo culture systems that subscribe to Good Manufacturing Practice 296 
and characterise their suppressive abilities prior to infusion into patients (Putnam et al., 2013; Haase 297 
et al., 2015).  Concerns have also arisen that some Tregs might lose FOXP3 expression and adopt an 298 
effector Th17 phenotype after infusion (Hori, 2011; Komatsu et al., 2014), possibly worsening the 299 
autoimmune disease.  Nevertheless, the process of isolating, expanding and re-infusing autologous 300 
Tregs has been completed in people with type 1 diabetes mellitus and Crohn’s disease.  Of the twelve 301 
children with diabetes mellitus who received autologous Tregs, eight achieved clinical remission, with 302 
no significant adverse events reported in any patient and appropriate and sustained responses to 303 
routine vaccination (Marek-Trzonkowska et al., 2014).  Administration of Tregs to patients with 304 
Crohn’s disease resulted in a greater frequency of adverse effects (including exacerbation of 305 
gastrointestinal disease (n=11) and thrombosis/thrombophlebitis (n=2)), with some form of response 306 
in eight of twenty patients overall (Desreumaux et al., 2012).  307 
 308 
There are many preliminary steps that would also need to be taken before Treg cell therapy could 309 
become a reality in dogs, including more thorough phenotyping of the Treg population, demonstration 310 
of its stability in response to an inflammatory setting and generation of a protocol that could be used 311 
reliably and safely to expand the population ex vivo.  In people, expansion of the Tregs to a number 312 
considered suitable for infusion also generally requires several weeks of repeated stimulation with 313 
anti-CD3 and anti-CD28 antibodies in a medium enriched with IL-2 (Putnam et al, 2013); this 314 
timescale may not be compatible with treatment of an autoimmune disease that often has an acute 315 
onset, though it could be useful to curtail regimens involving broad-spectrum immunosuppressive 316 
drugs. 317 
 318 
Low dose interleukin 2 therapy:  Interleukin 2 was traditionally considered to be a cytokine that 319 
stimulated effector T cell proliferation and differentiation, but mice that could not produce the 320 
cytokine were unexpectedly found to develop spontaneous autoimmune diseases (Sadlack et al., 321 
1993).  Interestingly, IL-2 gene knockouts on the Balb/c mouse background caused fatal AIHA within 322 
five weeks, which was related to deficiency of the Treg compartment, uncontrolled proliferation of 323 
effector T cells and production of autoantibodies (Sadlack et al., 1995).  Similar abnormalities were 324 
detected in mice lacking the IL-2 receptor alpha chain (CD25), which is constitutively expressed at 325 
high levels by Tregs (Willerford et al., 1995), and in people with missense mutations in the equivalent 326 
gene (Sharfe et al., 1997). 327 
 328 
Since the recognition that IL-2 is required for maintenance of Treg numbers and activity, there has 329 
been interest in the use of the recombinant human cytokine for treatment of autoimmune diseases 330 
(Klatzmann and Abbas, 2015).  Administration of IL-2 at high doses has been associated with adverse 331 
effects, such as excessive production of other cytokines and increased capillary permeability 332 
(Rosenstein et al., 1986; Baluna and Vitetta, 1997), but low dose IL-2 therapy appears to be more 333 
promising in clinical practice.     334 
 335 
Low dose IL-2 therapy has been used in 10 people with vasculitis induced by hepatitis C infection, in 336 
whom it caused only mild and transient reactions, with no signs of vascular leak syndrome.  Clinical 337 
signs improved in eight of ten patients, with an increase in the average number of Tregs across the 338 
whole group (Saadoun et al., 2011).  In a separate open pilot study, IL-2 was administered at a low 339 
dose to five people with alopecia areata, with improvements in clinical disease score and 340 
immunohistochemical findings of scalp biopsies in four of five patients (Castela et al., 2014).  341 
 342 
Additional clinical trials are currently ongoing to evaluate low dose IL-2 in other human autoimmune 343 
diseases (Waldron-Lynch et al., 2014; Humrich et al., 2015), and this treatment could also be 344 
developed for canine use.  So far, only recombinant human IL-2 is available, and, while this product 345 
has been administered intralesionally for treatment of several types of cancer in dogs without apparent 346 
adverse effects (Konietscke et al., 2012; Haagsman et al., 2013; Ziekman et al., 2013; Den Otter et al., 347 
2015), there are no reports of its systemic administration.  An appropriate dose for treatment of 348 
autoimmune disease would also need to be established, as doses of IL-2 required to stimulate Tregs 349 
appear to differ between species (Klatzmann and Abbas, 2015).     350 
 351 
Emerging alternative therapies:  Several other forms of immunotherapy that modulate the signals 352 
determining survival of circulating lymphocytes are in varying stages of development, and these could 353 
also have application in the treatment of AIHA.  Maturation and survival of B cells in the periphery is 354 
dependent on interactions between the soluble molecule B lymphocyte stimulator (BLyS) and its 355 
receptor, BLyS receptor 3 (BR3), which is expressed on their surface (Cancro et al., 2009).  The 356 
concentration of BLyS regulates the size and nature of the mature B cell compartment, with higher 357 
concentrations resulting in greater numbers of B cells and also permitting B cells with autoreactive 358 
potential to survive (Cancro et al., 2009).  The serum concentration of BLyS was greater in people 359 
with AIHA compared to healthy controls in two studies; in one of these, the concentration correlated 360 
with indicators of clinical disease activity (Zhao et al., 2015) and decreased after treatment with 361 
glucocorticoids (Xu et al., 2015).   362 
 363 
These findings suggest that autoreactive B cells escaping suppression or deletion may be important in 364 
development of AIHA, providing further recourse for treatment using therapies that modulate serum 365 
concentrations of BLyS.  One such treatment is belimumab, a human monoclonal antibody product 366 
that binds to and inhibits soluble BLyS, resulting in decreased B cell proliferation, depletion of B cells 367 
(Baker et al., 2003) and improved control of disease activity in people with systemic lupus 368 
erythematosus (SLE)(Ginzler et al, 2013). 369 
 370 
Preservation of a functioning apoptotic pathway is essential to maintenance of tolerance in T cells 371 
because it permits cell death during selection in the thymus and after receipt of inhibitory signals from 372 
APCs (Tischner et al, 2010).  Conversely, overexpression of anti-apoptotic regulators in lymphocytes 373 
may contribute to development of SLE in people (Andre et al, 2007).  The Bcl family of cell 374 
signalling molecules includes pro- and anti-apoptotic members: Bcl-2 and Bcl-xL are major members 375 
of the latter group (Tischner et al., 2010).  Inhibitors of these molecules were developed primarily for 376 
treatment of lymphoma, but administration of the Bcl-2 family antagonist ABT-737 has also resulted 377 
in clinical improvements in murine models of SLE and rheumatoid arthritis (Bardwell et al, 2009). 378 
 379 
Finally, differentiation of activated T cells could be modulated using drugs that alter the activity of 380 
the transcription factors that determine commitment to a particular subset.  Recent efforts have 381 
focused on development of small molecule inhibitors of retinoic acid receptor-related orphan nuclear 382 
receptor (RORγt), the central transcription factor involved in differentiation of Th17 T cells.  So far, 383 
published work has shown clinical improvement in a murine model of multiple sclerosis after 384 
administration of a candidate molecule (Xiao et al., 2014), but similar products could be useful in 385 
people with AIHA as Th17 cells are present at increased frequency in these patients (Xu et al., 2012).      386 
 387 
Conclusions 388 
Several forms of novel immunotherapy are currently in active development, largely based on greater 389 
understanding of the regulatory processes that usually control autoimmune responses.  Some of these 390 
forms of therapy warrant considerable testing before they could be applied in client-owned animals in 391 
veterinary practice, but others are undergoing clinical trials at present, raising the exciting prospect of 392 
novel immunotherapies for treatment of canine IMHA in the future. 393 
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Figure 1: Schematic diagram to indicate parts of the immune response that are targeted by different 723 
forms of therapy.  Blue section indicates normal immune response against pathogenic bacteria; red 724 
section indicates autoimmune response against erythrocytes.  Broad-spectrum immunosuppressive 725 
agents affect many parts of the immune response (including several not shown), whereas emerging 726 
immunotherapies have a more specific action.  727 
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Abstract  29 
Therapy of autoimmune diseases in dogs and people currently relies on use of broad-spectrum 30 
immunosuppressive drugs, which are associated with unacceptable adverse effects in some patients. 31 
Detractions of broad-spectrum immunosuppressive drugs are particularly apparent in people and 32 
animals with autoimmune haemolytic anaemia (AIHA), in whom such therapy is often required at 33 
high doses and for prolonged periods.   Greater understanding of the immune aberrations that occur in 34 
patients with AIHA has permitted development of several forms of novel immunotherapy, which are 35 
intended to re-establish tolerance of self-antigens rather than suppress all parts of the immune system.  36 
Such therapies should be efficacious while still permitting normal responses to pathogens and 37 
inoculation.  Immunotherapies of particular interest include monoclonal antibodies that produce 38 
selective depletion of the B cell compartment to decrease autoantibody production, administration of 39 
peptide antigens by subcutaneous or sublingual routes to establish tolerance, adoptive transfer of 40 
regulatory T cells (Tregs), and administration of low dose recombinant interleukin 2 to encourage 41 
proliferation and activation of Tregs.  These therapies are in variable stages of development, with 42 
some being trialled in people and client-owned dogs, and others undergoing validation in 43 
experimental murine models.  Continued development of these immunotherapies is likely to lead to 44 
the introduction of several novel products for the management of autoimmune disease in veterinary 45 
practice in the future. 46 
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Introduction 56 
 57 
Autoimmune diseases are caused by the development of inappropriate immune responses directed 58 
against host antigens.  Ordinarily, the immune system remains tolerant of self-antigens through a 59 
number of mechanisms, beginning with deletion of autoreactive T cells in the thymus and B cells in 60 
bone marrow (Mouchess and Anderson, 2014).  This process is insufficient to maintain immune 61 
tolerance because not all autoreactive cells are deleted and because mature lymphocytes may be 62 
exposed to cryptic antigens, such as after entry into the eye, brain, testis or other immunologically 63 
privileged sites (Forrester et al., 2008).  The activity of mature T cells emigrating from the thymus is 64 
therefore regulated to limit development of responses to self-antigens, while permitting differentiation 65 
of effector cells capable of responding to exogenous insults.  This regulation, synonymous with 66 
maintenance of peripheral tolerance, is manifest in the complex interaction of physical barriers, 67 
soluble signalling molecules and synapses between cells of the innate and adaptive immune systems, 68 
of which one important participant is the regulatory T cell (Treg) (Sakaguchi et al., 2009).   69 
 70 
Regulatory T cells:  The term Treg is now generally applied to a group of CD4+ T cells recognised in 71 
mice and people by their surface expression of the interleukin (IL)-2 receptor alpha chain, CD25, and 72 
by expression of the transcription factor Forkhead box Protein 3 (FoxP3), which is required for their 73 
differentiation and function (Brunkow et al., 2001; Hori et al., 2003).  The presence of a functional 74 
thymus is required for development of these thymic Tregs (Kojima and Prehn, 1981), though similar 75 
cells can differentiate in the periphery (Yadav et al., 2013). As in other species, a group of CD4+ T 76 
cells that expresses FoxP3 and displays CD25 has been described in dogs (Garden et al., 2011; 77 
Knueppel et al., 2011; Pinheiro et al., 2011), in which they were also capable of suppressing non-78 
specific proliferation of T cells in vitro.  A more recent study of the markers expressed by human 79 
CD4+CD25+FOXP3+ T cells suggests that many different subdivisions of this group will be 80 
recognised in future using emerging methodologies such as flow spectrometry, though the functional 81 
characteristics of these sub-groups have yet to be investigated (Mason et al., 2015).   82 
Regulatory T cells are able to suppress the activation and proliferation of effector T cells (CD4+ cells 83 
with Th1, Th2, Th9, Th17 and other phenotypes) and cytotoxic T cells in vitro when the latter cells 84 
are activated by either polyclonal or specific antigenic stimuli (Thornton et al., 1998; Dieckmann et 85 
al., 2001; Wing et al., 2003).  Corresponding effects are observed in vivo, with suppression of 86 
transplant rejection and cessation of deleterious autoimmune responses observed after adoptive 87 
transfer of Tregs into experimental animals (Graca et al., 2002; Hoffmann et al., 2002; Buckner, 88 
2010).  The importance of Tregs is also demonstrated by mice that have undergone thymectomy 89 
(Kojima and Prehn, 1981; Sakaguchi et al., 1985), adult mice in which Tregs have been depleted 90 
pharmacologically (Ellis et al., 2013; Kim et al., 2007) and people and mice that are unable to express 91 
FOXP3/foxp3 in Tregs (Bennett et al., 2001; Brunkow et al., 2001; Wildin et al., 2001), all of which 92 
develop multisystemic autoimmune diseases.   93 
 94 
Investigations of Tregs in people with spontaneous autoimmune diseases have yielded results that are 95 
more equivocal, possibly because findings may depend on the types of samples collected and the 96 
gating strategies used to define Tregs using flow cytometry.  For example, in people with rheumatoid 97 
arthritis, the frequency of Tregs in blood has been reported to be normal (Aerts et al., 2008), increased 98 
(Han et al., 2008) or decreased (Cao et al., 2004) in different studies, whereas Tregs are consistently 99 
increased in synovial fluid of inflamed joints (Miyara et al., 2011).  Changes in peripheral blood 100 
Tregs in various human autoimmune diseases have been summarised elsewhere (Miyara et al., 2011; 101 
Grant et al., 2015). 102 
 103 
Preliminary investigations of Tregs in canine immune-mediated diseases have yielded similarly mixed 104 
results.  Decreased frequencies of Tregs were described in the blood of dogs with primary immune-105 
mediated thrombocytopaenia and chronic enteropathies compared to healthy control dogs in a small 106 
pilot study (Volkmann et al., 2014), but frequencies were not different from healthy dogs after the 107 
clinical signs of both diseases were controlled.  In a separate study, the proportion of T cells that 108 
expressed both CD4 and FoxP3 did not differ between healthy dogs and dogs with primary 109 
hypothyroidism (Miller et al., 2015). 110 
 111 
Immune-mediated haemolytic anaemia in people and dogs:  One autoimmune disease in which the 112 
role of Tregs is not fully defined is autoimmune haemolytic anaemia (AIHA), which was first 113 
described in a human patient by Vanlair and Masius in 1871 (Packman, 2001).  The disease is 114 
characterised by production of antibodies directed against normal glycoprotein antigens on the surface 115 
of erythrocytes.  Anti-erythrocyte antibodies are produced normally to assist in clearance of senescent 116 
cells (Lutz and Wipf, 1982); in people with AIHA, the antibodies facilitate complement-mediated 117 
intravascular haemolysis or phagocytosis of opsonised erythrocytes in the liver and spleen (Berentsen 118 
and Tundic, 2015), resulting in anaemia that is often severe.  Autoimmune haemolytic anaemia is 119 
classified according to the activity of autoantibodies at different temperatures: the most common form 120 
is ‘warm’ AIHA, in which antibodies are capable of causing haemolysis at 37oC, which differentiates 121 
the disease from several forms of cold agglutinating disease (CAD), in which antibodies are most 122 
active at 3-4oC (Berentsen and Tundic, 2015).  Warm AIHA bears strong resemblance to canine 123 
primary immune-mediated haemolytic anaemia (IMHA), which is considered to be the most common 124 
autoimmune disease of dogs (McCullough, 2003).  Both diseases cause severe anaemia that typically 125 
develops acutely and may be accompanied by pre-hepatic icterus (Swann and Skelly, 2011; Berentsen 126 
and Tundic, 2015).   127 
 128 
Studies of people with warm AIHA indicate that the aberrant autoimmune response may have a Th17 129 
phenotype; the frequency of Th17 cells in peripheral blood was increased in people with AIHA 130 
compared to healthy controls and these and the serum concentration of IL-17 were correlated with the 131 
severity of clinical disease (Hall et al., 2012; Xu et al., 2012).  A further study indicated that the 132 
frequency of Tregs was decreased in people with warm AIHA compared to healthy volunteers, and 133 
this also correlated with some markers of disease severity (Ahmad et al., 2011).  There are no 134 
published studies describing numbers or suppressive function of Tregs in dogs with primary IMHA, 135 
but this is an area of active investigation in our own laboratory.  A single abstract described an 136 
unusually high average frequency of Tregs as a proportion of total lymphocytes (24.84%) in seven 137 
affected dogs (Baek et al., 2013). 138 
 139 
Therapy of autoimmune diseases:  In clinical practice today, autoimmune diseases are treated with 140 
immunosuppressive agents that frequently have an effect on many parts of the immune system 141 
simultaneously.  While often effective, these drugs may be associated with adverse effects because 142 
they suppress immune responses directed at all antigens, including exogenous pathogens.  Also, 143 
because these drugs do not induce tolerance of self-antigens, there is a continued risk of relapse 144 
during and after treatment, such that a very long or indefinite course of treatment is often required.  145 
Owing to the detractions inherent in immunosuppressive treatment, much current research is directed 146 
at generation of immunomodulatory therapies that induce or re-instate peripheral tolerance of self-147 
antigens, either by altering responses of effector T cells or by increasing numbers or activity of Tregs 148 
(Figure 1). 149 
 150 
Rationale for and implications of immunosuppressive treatment:  There has been a pleasing and 151 
saleable symmetry about the use of immunosuppressive drugs for the treatment of autoimmune 152 
diseases in people and animals since the discovery and widespread production of the synthetic 153 
corticosteroids in the 1950s (Herzog and Oliveto, 1992).  Indeed, glucocorticoids remain the only 154 
group of drugs licensed for the treatment of autoimmune diseases in dogs and cats in the UK1 and, in 155 
a recent systematic review of evidence relating to the treatment of IMHA in dogs, we found that 156 
glucocorticoids had been administered to all of the 843 dogs from which data were derived (Swann 157 
and Skelly, 2013).  Use of prednisolone (or prednisone) alone seems to result in survival rates of up to 158 
65% at six months after diagnosis (Swann and Skelly, 2013), with similar response rates reported in 159 
people (Zanella and Barcellini, 2014).  There are concerns that long-term administration of these 160 
drugs may result in unacceptable adverse effects, largely due to iatrogenic recapitulation of Cushing’s 161 
syndrome and increased risk of thromboembolic disease (Rose et al., 2011). 162 
 163 
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In order to facilitate a polypharmaceutical approach to the management of autoimmune disease, 164 
several other immunosuppressive drugs have been used in medical and veterinary practice, as has 165 
been reviewed elsewhere (Whitley and Day, 2011; Zanella and Barcellini, 2014).  Adoption of 166 
combination therapies for treatment of dogs with IMHA is conceptually attractive but is not proven to 167 
result in improved survival or decreased prevalence of glucocorticoid-associated adverse effects 168 
(Swann and Skelly, 2013).  Indeed, concurrent use of immunosuppressive drugs that act on different 169 
components of the immune response may produce additional risks, such as development of cutaneous 170 
fungal infections in dogs receiving ciclosporin and glucocorticoids (Dowling et al., 2015). 171 
 172 
Greater understanding of the immunological changes that occur in people and animals with 173 
autoimmune diseases has also informed the use of some immunosuppressive drugs.  Epidemiological 174 
studies revealed that the alkylating agent cyclophosphamide had a paradoxical effect, causing immune 175 
stimulation at low doses and immunosuppression at high doses, as reviewed elsewhere (Heylmann et 176 
al., 2013).  Investigations in people and mice have shown that Tregs are particularly sensitive to the 177 
lymphotoxic effects of cyclophosphamide at low doses, favouring increased activity of effector 178 
components of the immune system (Brode and Cooke, 2008).  While this effect is beneficial to 179 
prevent immune evasion of neoplastic cells in patients receiving metronomic chemotherapy 180 
(Schabowsky et al., 2007), it is interesting to note that administration of cyclophosphamide was 181 
associated with a poorer outcome in dogs with IMHA in two small epidemiological studies (Reimer et 182 
al., 1999; Grundy and Barton, 2001), possibly related to its effects on Tregs.  In contrast, the same 183 
drug has been used at high doses in people to achieve control of AIHA that has not responded to 184 
glucocorticoids or other forms of conventional treatment, resulting in clinical remission in five of 185 
eight patients in one study (Moyo et al., 2002). 186 
 187 
Monoclonal antibody therapy:  People with AIHA who have failed treatment with glucocorticoids 188 
are frequently treated with rituximab, a human/murine chimeric monoclonal antibody specific for the 189 
human CD20 molecule.  Exclusive expression on the surface of B cells makes this molecule an 190 
attractive target in diseases characterised by autoantibody production; binding of rituximab facilitates 191 
complement-mediated destruction and antibody-mediated cell cytotoxicity, resulting in rapid 192 
depletion of the B cell compartment in blood, lymphoid tissue and bone marrow (Reff et al., 1994).  193 
Since the first report of its use in people with warm AIHA in 2002 (Zaja et al., 2002), more than 20 194 
studies have evaluated its effects.  A recent meta-analysis of data from 409 people concluded that the 195 
overall response rate was 79% (95% confidence interval [CI] 60-90%) in people with warm AIHA, 196 
and that the rate of overall and complete response was higher in this group of patients compared to 197 
those with other forms of AIHA in univariable meta-regression analysis (Reynaud et al., 2015).  In 198 
one study, the majority of patients making a complete response remained in remission for at least six 199 
months, with responses more likely in younger patients and those with a shorter duration of disease 200 
prior to receiving rituximab (Penalver et al, 2010; Barcellini et al, 2013; Reynaud et al, 2015).  201 
 202 
Monoclonal antibodies have a more restricted immunosuppressive effect than glucocorticoids and 203 
other broad-spectrum immunosuppressive drugs, but they still increase the risk of opportunistic 204 
infections.   Adverse effects were observed in approximately 14% (95% CI 9-21) of people treated 205 
with rituximab in the meta-analysis described in the preceding paragraph (Reynaud et al., 2015), with 206 
severe infections, neutropaenia and Pneumocystis jirovecii pneumonia representing the most inimical.  207 
Monoclonal antibodies, though usually humanised or composed of chimeric murine and human 208 
elements, may still be recognised as foreign antigens by the immune system, resulting in development 209 
of responses that neutralise their effects (Keiserman et al., 2014).  Finally, depletion of the B cell 210 
compartment may also create niches in the spleen that are conducive to survival of long-lived 211 
autoreactive plasma cells, which would not otherwise persist in the face of conventional 212 
immunosuppressive treatment.  This phenomenon has been demonstrated in studies of people with 213 
warm AIHA and immune-mediated thrombocytopaenia that received rituximab before undergoing 214 
splenectomy owing to failure to control their clinical signs (Mahevas et al., 2013; 2015), though this 215 
has not been associated with increased risk of relapse.     216 
 217 
Rituximab was manufactured for specificity to epitopes on the extracellular domain of human CD20.  218 
The structure of this domain varies among mammalian species (Polyak and Deans, 2002), but the 219 
functional importance of this diversity is unknown because the physiological ligand for CD20 has yet 220 
to be identified.  Consequent to these differences in structure, rituximab does not cross react with the 221 
extracellular domain of canine molecules (Jubala et al., 2005) and has no apparent therapeutic 222 
potential in this species, as demonstrated by failure to deplete B cells in an ex vivo model of B cell 223 
lymphoma (Impellizeri et al., 2006).  Nevertheless, established methodologies have been applied to 224 
develop monoclonal ‘caninised’ antibodies that bind CD20 and deplete B cells in dogs (Ito et al., 225 
2015; Rue et al., 2015).  One such product has been licensed in the United States, and clinical trials 226 
are currently ongoing to evaluate its efficacy in the management of canine lymphoma2 (Rodriguez et 227 
al., 2015).       228 
 229 
Autoantigen-specific immunotherapy:  Production of antibodies with high affinity for antigen does 230 
not occur without provision of stimulatory signals from T helper cells, which premise has led to 231 
renewed interest in the role of these cells in autoimmune diseases.  Naïve T cells become activated 232 
when they recognise their cognate antigens presented in the context of major histocompatibility 233 
(MHC) molecules, but mounting evidence suggests that the concentration, preparation and route of 234 
entry of the antigen into the body can have a major impact on the nature of the immune response that 235 
develops (Verhagen et al., 2015).  For example, experiments in the early twentieth Century showed 236 
that administration of pollen extracts to patients with pollen hypersensitivity (hay fever) by 237 
subcutaneous injection could alleviate or completely resolve their clinical signs, whereas the same 238 
allergens would be detrimental if encountered naturally (Ring and Gutermuth, 2011).  These 239 
observations led to the development of allergen-specific immunotherapy protocols for use in this and 240 
other hypersensitivity diseases (Jutel et al., 2015), and delivery of allergens by subcutaneous or 241 
sublingual routes is also widely practiced in veterinary medicine for management of canine atopic 242 
dermatitis (Olivry et al., 2015; Mueller et al., 2015).  243 
 244 
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Several experimental models suggest that the same process could be applied to control established 245 
autoimmune responses (Sabatos-Peyton et al., 2010).  This autoantigen-specific immunotherapy is 246 
based primarily on the ability to induce Th1, Th2 and Th17 cells to adopt a regulatory phenotype 247 
characterised by production of IL-10 (Meiler et al., 2008) and possibly by display of the surface 248 
markers CD49b and LAG-3 (Gagliani et al., 2013) in response to their cognate antigens.  Effector T 249 
cells are more likely to differentiate into these so-called Tr1 cells (also described as IL-10Tregs cells) 250 
when exposed to repeated, high doses of their cognate antigens delivered by subcutaneous injection, 251 
though, in patients with clinically active diseases, there are concerns that such dosing schedules could 252 
exacerbate of the autoimmune response.   253 
 254 
The latter phenomenon was observed in three patients with multiple sclerosis who received 255 
subcutaneous injections of a peptide derived from the immunodominant myelin basic protein.  These 256 
patients suffered more severe neurological abnormalities and brain inflammation (as indicated by 257 
magnetic resonance imaging) but were subsequently rescued by administration of glucocorticoids 258 
(Bielekova et al., 2000).  Elucidation of immunological changes revealed that administration of the 259 
autoantigen was associated with increased numbers of Th1 effector cells in the cerebrospinal fluid of 260 
some patients, rather than induction of anergy or differentiation of Tr1 cells.  While notably this study 261 
used an altered peptide antigen, in which some amino acids had been artificially substituted to modify 262 
the interaction at the synapse between T cell and MHC-peptide complex, this study demonstrates the 263 
risks inherent in autoantigen-specific immunotherapy and the need for a dosing schedule that 264 
minimises them.    265 
 266 
Autoantigen-specific immunotherapy has not been attempted in people with AIHA or dogs with 267 
IMHA, but this form of treatment could be feasible in both species because previous studies have 268 
identified several of the immunodominant self-antigens targeted by autoimmune responses.  In 269 
people, autoantibodies are most commonly specific for epitopes on the Rhesus polypeptides (Barker 270 
et al., 1992), and T cells from patients with AIHA showed a proliferative response in vitro to peptides 271 
derived from the Rhesus D molecule (Barker et al., 1997).  In dogs with IMHA, autoreactive T and B 272 
cells are more likely to be specific for glycophorin molecules, though patterns of reactivity to 273 
erythrocyte antigens do not appear to be as consistent between individuals as in people (Barker et al., 274 
1991; Corato et al., 1997). 275 
 276 
In people with warm AIHA, T cells that produce IL-10 in response to Rhesus D molecules have also 277 
been identified in the spleen and peripheral blood.   These cells were able to suppress production of 278 
the Th1-associated cytokine interferon gamma (IFNγ) in peripheral blood mononuclear cell cultures 279 
in vitro, contingent on their expression of CTLA-4 (Hall et al., 2002; Ward et al., 2008).  These 280 
studies suggest that Tr1 cells are present in the blood of people with AIHA, where they could be 281 
activated or induced by administration of autoantigen in an appropriate form. 282 
 283 
Cell-based therapy:  Whether or not defects in Treg frequency or function contribute to development 284 
of autoimmune diseases, there is growing evidence to suggest that they could be used as a therapeutic 285 
agent to re-establish tolerance of self-antigens.  In support of this notion, adoptive transfer of splenic 286 
CD4+CD25+ Tregs prevented production of anti-erythrocyte antibodies in mice that were 287 
subsequently injected repeatedly with rat erythrocytes to generate an autoimmune response (in the 288 
Playfair Marshall-Clarke model of AIHA)(Mqadmi et al., 2005).  Studies in other murine models of 289 
autoimmune disease have shown that similar adoptive transfers can ameliorate established 290 
autoimmune diseases and delay or prevent rejection of transplanted organs, as reviewed elsewhere 291 
(Singer et al., 2014).   292 
 293 
There have been numerous obstacles in the path to use Tregs as therapy for people with autoimmune 294 
diseases, including the need to isolate Tregs from peripheral blood using reliable phenotypic markers, 295 
expand the number of Tregs in ex vivo culture systems that subscribe to Good Manufacturing Practice 296 
and characterise their suppressive abilities prior to infusion into patients (Putnam et al., 2013; Haase 297 
et al., 2015).  Concerns have also arisen that some Tregs might lose FOXP3 expression and adopt an 298 
effector Th17 phenotype after infusion (Hori, 2011; Komatsu et al., 2014), possibly worsening the 299 
autoimmune disease.  Nevertheless, the process of isolating, expanding and re-infusing autologous 300 
Tregs has been completed in people with type 1 diabetes mellitus and Crohn’s disease.  Of the twelve 301 
children with diabetes mellitus who received autologous Tregs, eight achieved clinical remission, with 302 
no significant adverse events reported in any patient and appropriate and sustained responses to 303 
routine vaccination (Marek-Trzonkowska et al., 2014).  Administration of Tregs to patients with 304 
Crohn’s disease resulted in a greater frequency of adverse effects (including exacerbation of 305 
gastrointestinal disease (n=11) and thrombosis/thrombophlebitis (n=2)), with some form of response 306 
in eight of twenty patients overall (Desreumaux et al., 2012).  307 
 308 
There are many preliminary steps that would also need to be taken before Treg cell therapy could 309 
become a reality in dogs, including more thorough phenotyping of the Treg population, demonstration 310 
of its stability in response to an inflammatory setting and generation of a protocol that could be used 311 
reliably and safely to expand the population ex vivo.  In people, expansion of the Tregs to a number 312 
considered suitable for infusion also generally requires several weeks of repeated stimulation with 313 
anti-CD3 and anti-CD28 antibodies in a medium enriched with IL-2 (Putnam et al, 2013); this 314 
timescale may not be compatible with treatment of an autoimmune disease that often has an acute 315 
onset, though it could be useful to curtail regimens involving broad-spectrum immunosuppressive 316 
drugs. 317 
 318 
Low dose interleukin 2 therapy:  Interleukin 2 was traditionally considered to be a cytokine that 319 
stimulated effector T cell proliferation and differentiation, but mice that could not produce the 320 
cytokine were unexpectedly found to develop spontaneous autoimmune diseases (Sadlack et al., 321 
1993).  Interestingly, IL-2 gene knockouts on the Balb/c mouse background caused fatal AIHA within 322 
five weeks, which was related to deficiency of the Treg compartment, uncontrolled proliferation of 323 
effector T cells and production of autoantibodies (Sadlack et al., 1995).  Similar abnormalities were 324 
detected in mice lacking the IL-2 receptor alpha chain (CD25), which is constitutively expressed at 325 
high levels by Tregs (Willerford et al., 1995), and in people with missense mutations in the equivalent 326 
gene (Sharfe et al., 1997). 327 
 328 
Since the recognition that IL-2 is required for maintenance of Treg numbers and activity, there has 329 
been interest in the use of the recombinant human cytokine for treatment of autoimmune diseases 330 
(Klatzmann and Abbas, 2015).  Administration of IL-2 at high doses has been associated with adverse 331 
effects, such as excessive production of other cytokines and increased capillary permeability 332 
(Rosenstein et al., 1986; Baluna and Vitetta, 1997), but low dose IL-2 therapy appears to be more 333 
promising in clinical practice.     334 
 335 
Low dose IL-2 therapy has been used in 10 people with vasculitis induced by hepatitis C infection, in 336 
whom it caused only mild and transient reactions, with no signs of vascular leak syndrome.  Clinical 337 
signs improved in eight of ten patients, with an increase in the average number of Tregs across the 338 
whole group (Saadoun et al., 2011).  In a separate open pilot study, IL-2 was administered at a low 339 
dose to five people with alopecia areata, with improvements in clinical disease score and 340 
immunohistochemical findings of scalp biopsies in four of five patients (Castela et al., 2014).  341 
 342 
Additional clinical trials are currently ongoing to evaluate low dose IL-2 in other human autoimmune 343 
diseases (Waldron-Lynch et al., 2014; Humrich et al., 2015), and this treatment could also be 344 
developed for canine use.  So far, only recombinant human IL-2 is available, and, while this product 345 
has been administered intralesionally for treatment of several types of cancer in dogs without apparent 346 
adverse effects (Konietscke et al., 2012; Haagsman et al., 2013; Ziekman et al., 2013; Den Otter et al., 347 
2015), there are no reports of its systemic administration.  An appropriate dose for treatment of 348 
autoimmune disease would also need to be established, as doses of IL-2 required to stimulate Tregs 349 
appear to differ between species (Klatzmann and Abbas, 2015).     350 
 351 
Emerging alternative therapies:  Several other forms of immunotherapy that modulate the signals 352 
determining survival of circulating lymphocytes are in varying stages of development, and these could 353 
also have application in the treatment of AIHA.  Maturation and survival of B cells in the periphery is 354 
dependent on interactions between the soluble molecule B lymphocyte stimulator (BLyS) and its 355 
receptor, BLyS receptor 3 (BR3), which is expressed on their surface (Cancro et al., 2009).  The 356 
concentration of BLyS regulates the size and nature of the mature B cell compartment, with higher 357 
concentrations resulting in greater numbers of B cells and also permitting B cells with autoreactive 358 
potential to survive (Cancro et al., 2009).  The serum concentration of BLyS was greater in people 359 
with AIHA compared to healthy controls in two studies; in one of these, the concentration correlated 360 
with indicators of clinical disease activity (Zhao et al., 2015) and decreased after treatment with 361 
glucocorticoids (Xu et al., 2015).   362 
 363 
These findings suggest that autoreactive B cells escaping suppression or deletion may be important in 364 
development of AIHA, providing further recourse for treatment using therapies that modulate serum 365 
concentrations of BLyS.  One such treatment is belimumab, a human monoclonal antibody product 366 
that binds to and inhibits soluble BLyS, resulting in decreased B cell proliferation, depletion of B cells 367 
(Baker et al., 2003) and improved control of disease activity in people with systemic lupus 368 
erythematosus (SLE)(Ginzler et al, 2013). 369 
 370 
Preservation of a functioning apoptotic pathway is essential to maintenance of tolerance in T cells 371 
because it permits cell death during selection in the thymus and after receipt of inhibitory signals from 372 
APCs (Tischner et al, 2010).  Conversely, overexpression of anti-apoptotic regulators in lymphocytes 373 
may contribute to development of SLE in people (Andre et al, 2007).  The Bcl family of cell 374 
signalling molecules includes pro- and anti-apoptotic members: Bcl-2 and Bcl-xL are major members 375 
of the latter group (Tischner et al., 2010).  Inhibitors of these molecules were developed primarily for 376 
treatment of lymphoma, but administration of the Bcl-2 family antagonist ABT-737 has also resulted 377 
in clinical improvements in murine models of SLE and rheumatoid arthritis (Bardwell et al, 2009). 378 
 379 
Finally, differentiation of activated T cells could be modulated using drugs that alter the activity of 380 
the transcription factors that determine commitment to a particular subset.  Recent efforts have 381 
focused on development of small molecule inhibitors of retinoic acid receptor-related orphan nuclear 382 
receptor (RORγt), the central transcription factor involved in differentiation of Th17 T cells.  So far, 383 
published work has shown clinical improvement in a murine model of multiple sclerosis after 384 
administration of a candidate molecule (Xiao et al., 2014), but similar products could be useful in 385 
people with AIHA as Th17 cells are present at increased frequency in these patients (Xu et al., 2012).      386 
 387 
Conclusions 388 
Several forms of novel immunotherapy are currently in active development, largely based on greater 389 
understanding of the regulatory processes that usually control autoimmune responses.  Some of these 390 
forms of therapy warrant considerable testing before they could be applied in client-owned animals in 391 
veterinary practice, but others are undergoing clinical trials at present, raising the exciting prospect of 392 
novel immunotherapies for treatment of canine IMHA in the future. 393 
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